(19)
(11) EP 2 068 935 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.09.2011 Bulletin 2011/37

(45) Mention of the grant of the patent:
13.04.2011 Bulletin 2011/15

(21) Application number: 07818168.2

(22) Date of filing: 14.09.2007
(51) International Patent Classification (IPC): 
A61K 47/48(2006.01)
C07K 14/52(2006.01)
 C07K 14/47(2006.01)
A61M 25/00(2006.01)
(86) International application number:
PCT/EP2007/008029
(87) International publication number:
WO 2008/031612 (20.03.2008 Gazette 2008/12)

(54)

POLYMER CONJUGATES OF BOX-A OF HMGB1 AND BOX-A VARIANTS OF HMGB1

POLYMERKONJUGATE VON BOX-A VON HMGB1 UND BOX-A-VARIANTEN VON HMGB1

CONJUGUES POLYMERES D'UNE BOITE A DE HMGB1 ET VARIANTES DE LA BOITE A DE HMGB1

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 15.09.2006 EP 06019362
05.03.2007 US 904776 P

(43) Date of publication of application:
17.06.2009 Bulletin 2009/25

(73) Proprietor: Creabilis Therapeutics s.r.l.
10010 Colleretto Giacosa (TO) (IT)

(72) Inventors:
  • TRAVERSA, Silvio
    10010 Palazzo Canavese (IT)
  • LORENZETTO, Chiara
    10068 Villafranca Piemonte (IT)
  • MAINERO, Valentina
    10015 Ivrea (TO) (IT)
  • MORENA, Sebastiano
    10034 Chivasso (IT)
  • FUMERO, Silvano
    10015 Ivrea (IT)
  • BECCARIA, Luca
    10015 Ivrea (IT)

(74) Representative: Weiss, Wolfgang et al
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München
81635 München (DE)


(56) References cited: : 
WO-A-02/092004
WO-A-2006/024547
 WO-A-2006/012373
   
  • YAMADA ET AL: "New high mobility group box 1 assay system" CLINICA CHIMICA ACTA, AMSTERDAM, NL, vol. 372, no. 1-2, 23 June 2006 (2006-06-23), pages 173-178, XP005623667 ISSN: 0009-8981
  • PASUT G. ET AL: 'Protein, peptide and non-peptide drug PEGylation for therapeutic application' EXPERT OPINION ON THERAPEUTIC PATENTS vol. 14, no. 6, 2004, pages 859 - 893, XP001202106
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).